After 10 years of follow-up, the cumulative incidence of breast cancer was significantly lower for BRCA1/2 mutation carriers who used ET (12%) compared to those who used EPT (22%; P = 0.04). The gene discussed is BRCA1; the disease is breast carcinoma.